Statement of Translational Relevance
Multiple myeloma is an incurable blood cancer. MAGE-A3 is a cancer-associated gene that is commonly expressed in multiple myeloma and correlates with higher frequencies of proliferating malignant cells. The results presented here show that expression of MAGE-A3 in patient specimens also correlated to relapse of multiple myeloma, suggesting a pathogenic role in progression of disease. Silencing of MAGE-A3 in myeloma cell lines and patient cells resulted in activation of intrinsic apoptosis due to p53-dependent expression of Bax and survivin by p53-dependent and independent mechanisms. MAGE-A3 appeared to contribute to progression of disease by promoting resistance to apoptosis in proliferating multiple myeloma cells. Therefore, MAGE-A3 is a promising therapeutic target in multiple myeloma, and strategies targeting it, such as
Introduction
The type I Melanoma Antigen GEnes (MAGE-A, B, and C) belong to the CancerTestis antigen (CTAg) group of tumor-associated genes. CTAg are expressed in a broad range of human cancers, but their normal expression is restricted to immunologically "privileged" tissues, including developing germ cells and trophoblastic tissue such as placenta (1) . For these reasons, CTAg have been investigated as targets for therapeutic tumor vaccines (2) . Their widespread expression in cancer also suggests that CTAg may have oncogenic activity and may be a novel class of therapeutic targets amenable to pharmacologic intervention. We previously reported that MAGE-A3 and CT7 (MAGE-C1) were detected in more than 70% of tumor specimens from patients with stage III (Durie-Salmon Staging) multiple myeloma (MM) (3) , an incurable malignancy of plasma cells that is the second most common hematologic cancer (4) . The patients in this study were a heterogenous group, including newly diagnosed, relapsed, and refractory cases. did not appear to regulate transcription of the p53 gene itself. However, Yang and colleagues reported that MAGE proteins interacted with the RING domain protein TRIM28/Kap1 and suppressed transcription of p53 in human and mouse melanoma cell lines, and that silencing of type I MAGEs also induced apoptosis (6) . Silencing of MAGE-A3 or CT7 expression by small interfering (si)RNA transfection appeared to reduce viability in human myeloma cell lines (HMCL) (7) , but the underlying mechanism was not explored. More recently, Doyle and colleagues used biochemical methods to demonstrate that MAGE/RING domain protein complexes function as E3 ubiquitin (Ub) ligases (8) . Several MAGE proteins associated with TRIM28/Kap1, and the MAGE-A2
and -C2 complexes were capable of polyubiquitinylating p53, targeting it for proteasomal degradation. This report of a biochemical function for MAGE was a groundbreaking revelation; however, it remains to be determined whether this activity is responsible for the effects of type I MAGE on survival and if p53 is the sole or dominant target substrate in myeloma cells.
To investigate the role of type I MAGEs in the pathogenesis and progression of MM, we examined their expression by immunohistochemistry (IHC) in an independent set of samples from two critical clinical milestones; newly diagnosed, untreated patients and patients who had relapsed after chemotherapy. Our data revealed that both the 
Materials and Methods

Patient samples
Specimens from patients diagnosed with multiple myeloma (9) were obtained at the Weill-Cornell Medical Center or New York University Clinical Cancer Center under Institutional Review Board-approved sample collection protocols (WCMC IRB #1000-422 and NYU IRB #06-523) in accordance with the Declaration of Helsinki.
Immunohistochemical Analysis IHC of bone marrow biopsies was performed as described previously (10) .
Briefly, primary antibodies were: M3H67 (MAGE-A3), CT7-33 (CT7), CT10 (CT10), MA454 (MAGE-A1), 57B (MAGE-A4), and E978 (NY-ESO-1), all provided by the Ludwig Institute for Cancer Research. Slides were blinded to the pathologist in regards to newly diagnosed versus relapsed status. Images were acquired as JPEG format files with a Nikon Coolpix 990 digital camera. Minor adjustments of brightness, contrast, and color solely for the purpose of legibility were made with Adobe Photoshop 7.0 for Windows (Adobe Systems Inc., San Jose, CA).
Plasma cell proliferation index assay PCPI was performed as previously described (11) . To compute the plasma cellspecific proliferation index (PCPI), 500 cells with a positive membranous CD138 signal were counted; each of those cells was scored as proliferating (containing a brown Ki-67 + nucleus) or non-proliferating (containing a blue, counter-stained, Ki-67-negative nucleus). The PCPI was reported as a percentage.
Research. (MAGE-C2) were also commonly detected, their frequencies of expression were not increased in relapsed patients ( fig. 1B) , although the grading of CT7 expression appeared to increase with progression of disease (suppl. fig. 1A ). Other CTAgs (MAGE-A1, MAGE-A4, and NY-ESO-1) were detected in less than 20% of patients in either group.
Proliferation in new and relapsed specimens was examined by Plasma Cell Proliferation Index (PCPI), defined as the percentage of myeloma cells expressing both the plasma cell marker CD138 and the proliferation marker Ki-67 (11) . As expected, the average PCPI was significantly higher in relapsed patients (19.0 ± 3.5%) compared to newly diagnosed (6.9 ± 1.3%, p < 0.0002, fig. 1D ) (12) . Therefore, although CT7 and MAGE-A3 were the predominant type I MAGEs expressed in MM, MAGE-A3 was distinguished by unique correlations with progression of disease and higher frequencies of Ki-67+ myeloma cells.
Loss of MAGE-A does not impair cell cycling in HMCL and primary myeloma cells
To investigate the mechanisms by which MAGE-A3 contributes to progression in MM, we silenced its expression in the HMCL MM.1r and H929, both of which express wt p53, and in ARP-1, which bears homozygous deletions of the TP53 loci on chromosome 17. We also used polyclonal primary cells (Pt #1) that had a monoallelic deletion of TP53 by fluorescence in situ hybridization, and sequencing of the other TP53 allele revealed a loss-of-function mutation in the DNA-binding region of exon 7, rendering them p53-null (suppl. fig. 2A, B) . MAGE-A3 was silenced with targeted lentiviral shRNA constructs (suppl. fig. 1B ) that demonstrated high transduction efficiency and low background toxicity. Two distinct constructs (shMA 129750 and 128375) silenced MAGE-A3 mRNA and protein expression compared to non-target shRNA-transduced (shNT) and untreated negative control (Con) cells ( fig. 2A and B) .
Subsequent experiments were performed with shMA 128375. This construct also silenced MAGE-A1 (suppl. fig. 1C ), most likely due to the high degree of sequence conservation among the MAGE-A family (13, 14) . CT7 mRNA levels in ARP-1 and Pt #1 cells were not affected by shMA 128375 (suppl. fig. 1D ). Since the potential activity of MAGE-A1 and other -A family members could not be formally excluded in these shRNA experiments, the target genes will be referred to collectively as "MAGE-A."
Research. 
However, it should be noted that MAGE-A1 was detected in less than 20% of patient samples by IHC (fig. 1B ). . 2D ), suggesting that the loss was due to cell death rather than a block in progression through the G1 cell cycle checkpoints. Corroborating this observation, silencing of MAGE-A in MM.1r did not perturb the ratio of cyclin-dependent kinase (CDK)4/CDK6-specific phosphorylation of Rb to total Rb compared to controls at 48 hrs (suppl. fig. 3A ), indicating that cell cycle progression through mid-G1 was intact. Total 
MAGE-
of CDK4 or CDK6 is central to loss of cell cycle control in myeloma (13) , these data confirmed that MAGE-A is not required for cell cycle progression through G1. The
CDK inhibitors p21
Cip1 and p27 Kip1 can act in both G1 and G2/M to mediate cell cycle arrest. The expression of p21 and p27 proteins also remained unchanged upon silencing of MAGE-A, despite an increase in p21 mRNA (suppl. fig. 3B-C) . Collectively, these data demonstrated that MAGE-A is required to maintain myeloma cell survival, particularly survival of S phase cells in the presence of p53, but is dispensable for cell cycling.
Silencing of MAGE-A triggers the intrinsic apoptosis pathway in proliferating myeloma cells
This led us to investigate the mechanisms by which silencing MAGE-A induced cell death. We first assessed apoptotic versus necrotic cell death in this system. 3E ). Caspase-9 cleavage/activation was also evident after MAGE-A silencing in p53 +/+ MM.1r but not in p53 -/-ARP-1, and very little caspase-9 was detected in p53 mut/-Pt #1 cells. These data demonstrated that MAGE-A inhibits intrinsic apoptosis in both p53
Silencing of MAGE-
+/+ and p53-null myeloma cells.
MAGE-A regulates Bax and survivin through p53-dependent mechanisms.
Having demonstrated that MAGE-A antagonized intrinsic apoptosis in MM.1r, we investigated expression of pro-and anti-apoptotic Bcl-2 genes in these cells. MAGE-A silencing in MM.1r lead to increased mRNA expression of pro-apoptotic Bax and Bak ( The lentiviral shRNA constructs in these experiments efficiently silenced MAGE-A1 as well as MAGE-A3, which is likely a reflection of the extensive sequence homology shared by this family (13) . However, MAGE-A1 was only detected in a minority of samples in this study and in our previous set of patients (3) , suggesting that MAGE-A3 plays a dominant role in vivo. Several MAGE-A family members and 
MAGE-C2 complex with TRIM28/Kap1 to form E3 ubiquitin ligases, and p53 is one of their targets for proteasomal degradation (8) . The results presented here indicate this activity reduces p53 protein in myeloma cells and decreases apoptosis. However, since apoptosis and down-regulation of survivin were also observed after MAGE-A silencing in cells that lacked functional p53, it is likely that non-p53 substrates of MAGE-A3/TRIM28 Ub ligase activity contribute to inhibition of apoptosis by regulating survival factors such as survivin.
Silencing of CT7 by siRNA transfection was reported to decrease viability in MM cell lines (7) . In our hands, silencing of MAGE-A by lentiviral shRNA transduction in ARP-1 and Pt #1 did not affect CT7 expression, but expression of CT7 in the absence of MAGE-A was not sufficient to prevent apoptosis. This discrepancy may be due to differences in RNA interference efficiency and greater background cell death with siRNA transfection. Although CT7 is commonly expressed in MM and its expression appears to be an early event in MM pathogenesis (3, 21) , it is unknown whether it has a similar spectrum of activity as MAGE-A family members. Further investigation is needed to illuminate the role of CT7 in MM pathogenesis. 
agents. These may be combined with vaccines in multi-targeted, MAGE-specific therapy designed to induce apoptosis in proliferating MM cells or make them more susceptible to chemotherapy-induced apoptosis, resulting in durable remission of this currently incurable disease. Proof of principle in MM may lead to broader application in other cancers that express type I MAGE. These include lung, breast, prostate and skin cancers, among the leading causes of cancer death. 
